(2R,3S,4S,5R,6R)-3,4-Dihydroxy-6-[(2R,3R,4R,5R,6S)-6-hydroxy-2-(hydroxymethyl)-5-(sulfoamino)-4-sulfooxyoxan-3-yl]oxy-5-sulfooxyoxane-2-carboxylic acid

Term ID

CHEBI:155284

Synonyms

2-O-sulfo-alpha-L-ido-hexopyranosyluronic acid-(1->4)-2-deoxy-3-O-sulfo-2-sulfoamino-alpha-D-gluco-hexopyranose
IdoA2S(a1-4)a-GlcNS3S

Definition

References

glygen:G95020NU
glytoucan:G95020NU

Ontology

ChEBI ( EBI )

Relationships

Phenotype

Phenotype resulting from (2R,3S,4S,5R,6R)-3,4-Dihydroxy-6-[(2R,3R,4R,5R,6S)-6-hydroxy-2-(hydroxymethyl)-5-(sulfoamino)-4-sulfooxyoxan-3-yl]oxy-5-sulfooxyoxane-2-carboxylic acid

Phenotype where environments contain (2R,3S,4S,5R,6R)-3,4-Dihydroxy-6-[(2R,3R,4R,5R,6S)-6-hydroxy-2-(hydroxymethyl)-5-(sulfoamino)-4-sulfooxyoxan-3-yl]oxy-5-sulfooxyoxane-2-carboxylic acid

Phenotype modified by environments containing (2R,3S,4S,5R,6R)-3,4-Dihydroxy-6-[(2R,3R,4R,5R,6S)-6-hydroxy-2-(hydroxymethyl)-5-(sulfoamino)-4-sulfooxyoxan-3-yl]oxy-5-sulfooxyoxane-2-carboxylic acid

Phenotype affecting (2R,3S,4S,5R,6R)-3,4-Dihydroxy-6-[(2R,3R,4R,5R,6S)-6-hydroxy-2-(hydroxymethyl)-5-(sulfoamino)-4-sulfooxyoxan-3-yl]oxy-5-sulfooxyoxane-2-carboxylic acid

Human Disease Model